APO Research
Talk to an analyst

APO RESEARCH · REPORT

Paediatric Influenza Prevention

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Paediatric Influenza Prevention Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchPaediatric Influenza Prevention Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Paediatric Influenza Prevention Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Paediatric Influenza Prevention Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Paediatric Influenza Prevention Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Paediatric Influenza Prevention Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Paediatric Influenza Prevention market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Paediatric Influenza Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Paediatric Influenza Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Paediatric Influenza Prevention is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Paediatric Influenza Prevention market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Paediatric Influenza Prevention market include Sanofi, Jiangsu GDK, GSK, Viatris, Sinovac, KM Biologics, Hulan Bio, CSL and CCBIO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Paediatric Influenza Prevention market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Paediatric Influenza Prevention and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Paediatric Influenza Prevention sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Paediatric Influenza Prevention market size, projected growth trends, production technologies, key applications, and end-use industries.

Paediatric Influenza Prevention Segment by Company

Sanofi

Jiangsu GDK

GSK

Viatris

Sinovac

KM Biologics

Hulan Bio

CSL

CCBIO

BCHT

AstraZeneca

Paediatric Influenza Prevention Segment by Type

Nasal Spray

Injection

Paediatric Influenza Prevention Segment by Application

Public

Private

Paediatric Influenza Prevention Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Paediatric Influenza Prevention status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Paediatric Influenza Prevention market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Paediatric Influenza Prevention significant trends, drivers, influence factors in global and regions.

6. To analyze Paediatric Influenza Prevention competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paediatric Influenza Prevention market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Paediatric Influenza Prevention and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paediatric Influenza Prevention.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Paediatric Influenza Prevention market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Paediatric Influenza Prevention industry.

Chapter 3: Detailed analysis of Paediatric Influenza Prevention manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Paediatric Influenza Prevention in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Paediatric Influenza Prevention in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Paediatric Influenza Prevention Industry Trends Table 2. Paediatric Influenza Prevention Industry Drivers Table 3. Paediatric Influenza Prevention Industry Opportunities and Challenges Table 4. Paediatric Influenza Prevention Industry Restraints Table 5. Global Paediatric Influenza Prevention Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Paediatric Influenza Prevention Revenue Share by Company (2021-2026) Table 7. Global Paediatric Influenza Prevention Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Paediatric Influenza Prevention Sales Volume Share by Company (2021-2026) Table 9. Global Paediatric Influenza Prevention Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Paediatric Influenza Prevention Company Ranking, (2024-2026) & (USD Million) Table 11. Global Paediatric Influenza Prevention Key Company Manufacturing Base & Headquarters Table 12. Global Paediatric Influenza Prevention Company, Product Type & Application Table 13. Global Paediatric Influenza Prevention Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Paediatric Influenza Prevention by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Nasal Spray Table 18. Significant Companies of Injection Table 19. Global Paediatric Influenza Prevention Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Paediatric Influenza Prevention Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Paediatric Influenza Prevention Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Paediatric Influenza Prevention Sales Volume Share by Type (2021-2026) Table 23. Global Paediatric Influenza Prevention Sales Volume Share by Type (2027-2032) Table 24. Global Paediatric Influenza Prevention Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Paediatric Influenza Prevention Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Paediatric Influenza Prevention Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Paediatric Influenza Prevention Sales Value Share by Type (2021-2026) Table 28. Global Paediatric Influenza Prevention Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Public Table 30. Significant Companies of Private Table 31. Global Paediatric Influenza Prevention Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Paediatric Influenza Prevention Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Paediatric Influenza Prevention Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Paediatric Influenza Prevention Sales Volume Share by Application (2021-2026) Table 35. Global Paediatric Influenza Prevention Sales Volume Share by Application (2027-2032) Table 36. Global Paediatric Influenza Prevention Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Paediatric Influenza Prevention Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Paediatric Influenza Prevention Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Paediatric Influenza Prevention Sales Value Share by Application (2021-2026) Table 40. Global Paediatric Influenza Prevention Sales Value Share by Application (2027-2032) Table 41. Global Paediatric Influenza Prevention Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Paediatric Influenza Prevention Sales by Region (2021-2026) & (K Units) Table 43. Global Paediatric Influenza Prevention Sales Market Share by Region (2021-2026) Table 44. Global Paediatric Influenza Prevention Sales by Region (2027-2032) & (K Units) Table 45. Global Paediatric Influenza Prevention Sales Market Share by Region (2027-2032) Table 46. Global Paediatric Influenza Prevention Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Paediatric Influenza Prevention Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Paediatric Influenza Prevention Sales Value Share by Region (2021-2026) Table 49. Global Paediatric Influenza Prevention Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Paediatric Influenza Prevention Sales Value Share by Region (2027-2032) Table 51. Global Paediatric Influenza Prevention Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Paediatric Influenza Prevention Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Paediatric Influenza Prevention Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Paediatric Influenza Prevention Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Paediatric Influenza Prevention Sales by Country (2021-2026) & (K Units) Table 56. Global Paediatric Influenza Prevention Sales Market Share by Country (2021-2026) Table 57. Global Paediatric Influenza Prevention Sales by Country (2027-2032) & (K Units) Table 58. Global Paediatric Influenza Prevention Sales Market Share by Country (2027-2032) Table 59. Global Paediatric Influenza Prevention Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Paediatric Influenza Prevention Sales Value Market Share by Country (2021-2026) Table 61. Global Paediatric Influenza Prevention Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Paediatric Influenza Prevention Sales Value Market Share by Country (2027-2032) Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sanofi Paediatric Influenza Prevention Product Portfolio Table 67. Sanofi Recent Development Table 68. Jiangsu GDK Company Information Table 69. Jiangsu GDK Business Overview Table 70. Jiangsu GDK Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Jiangsu GDK Paediatric Influenza Prevention Product Portfolio Table 72. Jiangsu GDK Recent Development Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. GSK Paediatric Influenza Prevention Product Portfolio Table 77. GSK Recent Development Table 78. Viatris Company Information Table 79. Viatris Business Overview Table 80. Viatris Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Viatris Paediatric Influenza Prevention Product Portfolio Table 82. Viatris Recent Development Table 83. Sinovac Company Information Table 84. Sinovac Business Overview Table 85. Sinovac Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sinovac Paediatric Influenza Prevention Product Portfolio Table 87. Sinovac Recent Development Table 88. KM Biologics Company Information Table 89. KM Biologics Business Overview Table 90. KM Biologics Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. KM Biologics Paediatric Influenza Prevention Product Portfolio Table 92. KM Biologics Recent Development Table 93. Hulan Bio Company Information Table 94. Hulan Bio Business Overview Table 95. Hulan Bio Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hulan Bio Paediatric Influenza Prevention Product Portfolio Table 97. Hulan Bio Recent Development Table 98. CSL Company Information Table 99. CSL Business Overview Table 100. CSL Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. CSL Paediatric Influenza Prevention Product Portfolio Table 102. CSL Recent Development Table 103. CCBIO Company Information Table 104. CCBIO Business Overview Table 105. CCBIO Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. CCBIO Paediatric Influenza Prevention Product Portfolio Table 107. CCBIO Recent Development Table 108. BCHT Company Information Table 109. BCHT Business Overview Table 110. BCHT Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. BCHT Paediatric Influenza Prevention Product Portfolio Table 112. BCHT Recent Development Table 113. AstraZeneca Company Information Table 114. AstraZeneca Business Overview Table 115. AstraZeneca Paediatric Influenza Prevention Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. AstraZeneca Paediatric Influenza Prevention Product Portfolio Table 117. AstraZeneca Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Paediatric Influenza Prevention Distributors List Table 121. Paediatric Influenza Prevention Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Paediatric Influenza Prevention Product Image Figure 2. Global Paediatric Influenza Prevention Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Paediatric Influenza Prevention Sales Value (2021-2032) & (US$ Million) Figure 4. Global Paediatric Influenza Prevention Sales (2021-2032) & (K Units) Figure 5. Global Paediatric Influenza Prevention Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Paediatric Influenza Prevention Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Nasal Spray Image Figure 10. Injection Image Figure 11. Global Paediatric Influenza Prevention Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Paediatric Influenza Prevention Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Paediatric Influenza Prevention Sales Volume Share by Type (2021-2032) Figure 14. Global Paediatric Influenza Prevention Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Paediatric Influenza Prevention Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Paediatric Influenza Prevention Sales Value Share by Type (2021-2032) Figure 17. Public Image Figure 18. Private Image Figure 19. Global Paediatric Influenza Prevention Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Paediatric Influenza Prevention Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Paediatric Influenza Prevention Sales Volume Share by Application (2021-2032) Figure 22. Global Paediatric Influenza Prevention Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Paediatric Influenza Prevention Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Paediatric Influenza Prevention Sales Value Share by Application (2021-2032) Figure 25. Global Paediatric Influenza Prevention Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Paediatric Influenza Prevention Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Paediatric Influenza Prevention Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Paediatric Influenza Prevention Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Paediatric Influenza Prevention Sales Value (2021-2032) & (US$ Million) Figure 30. North America Paediatric Influenza Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Paediatric Influenza Prevention Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Paediatric Influenza Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Paediatric Influenza Prevention Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Paediatric Influenza Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Paediatric Influenza Prevention Sales Value (2021-2032) & (US$ Million) Figure 36. South America Paediatric Influenza Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Paediatric Influenza Prevention Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Paediatric Influenza Prevention Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Paediatric Influenza Prevention Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Paediatric Influenza Prevention Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Nasal Spray
  • Injection
Applications
  • Public
  • Private
Companies covered
  • Sanofi
  • Jiangsu GDK
  • GSK
  • Viatris
  • Sinovac
  • KM Biologics
  • Hulan Bio
  • CSL
  • CCBIO
  • BCHT
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Paediatric Influenza Prevention Sales Value (2021-2032)
  4. 1.2.2 Global Paediatric Influenza Prevention Sales Volume (2021-2032)
  5. 1.2.3 Global Paediatric Influenza Prevention Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Paediatric Influenza Prevention Market Dynamics
  1. 2.1 Paediatric Influenza Prevention Industry Trends
  2. 2.2 Paediatric Influenza Prevention Industry Drivers
  3. 2.3 Paediatric Influenza Prevention Industry Opportunities and Challenges
  4. 2.4 Paediatric Influenza Prevention Industry Restraints
3 Paediatric Influenza Prevention Market by Company
  1. 3.1 Global Paediatric Influenza Prevention Company Revenue Ranking in 2025
  2. 3.2 Global Paediatric Influenza Prevention Revenue by Company (2021-2026)
  3. 3.3 Global Paediatric Influenza Prevention Sales Volume by Company (2021-2026)
  4. 3.4 Global Paediatric Influenza Prevention Average Price by Company (2021-2026)
  5. 3.5 Global Paediatric Influenza Prevention Company Ranking (2024-2026)
  6. 3.6 Global Paediatric Influenza Prevention Company Manufacturing Base and Headquarters
  7. 3.7 Global Paediatric Influenza Prevention Company Product Type and Application
  8. 3.8 Global Paediatric Influenza Prevention Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Paediatric Influenza Prevention Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Paediatric Influenza Prevention Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Paediatric Influenza Prevention Market by Type
  1. 4.1 Paediatric Influenza Prevention Type Introduction
  2. 4.1.1 Nasal Spray
  3. 4.1.2 Injection
  4. 4.2 Global Paediatric Influenza Prevention Sales Volume by Type
  5. 4.2.1 Global Paediatric Influenza Prevention Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Paediatric Influenza Prevention Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Paediatric Influenza Prevention Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Paediatric Influenza Prevention Sales Value by Type
  9. 4.3.1 Global Paediatric Influenza Prevention Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Paediatric Influenza Prevention Sales Value by Type (2021-2032)
  11. 4.3.3 Global Paediatric Influenza Prevention Sales Value Share by Type (2021-2032)
5 Paediatric Influenza Prevention Market by Application
  1. 5.1 Paediatric Influenza Prevention Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Paediatric Influenza Prevention Sales Volume by Application
  5. 5.2.1 Global Paediatric Influenza Prevention Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Paediatric Influenza Prevention Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Paediatric Influenza Prevention Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Paediatric Influenza Prevention Sales Value by Application
  9. 5.3.1 Global Paediatric Influenza Prevention Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Paediatric Influenza Prevention Sales Value by Application (2021-2032)
  11. 5.3.3 Global Paediatric Influenza Prevention Sales Value Share by Application (2021-2032)
6 Paediatric Influenza Prevention Regional Sales and Value Analysis
  1. 6.1 Global Paediatric Influenza Prevention Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Paediatric Influenza Prevention Sales by Region (2021-2032)
  3. 6.2.1 Global Paediatric Influenza Prevention Sales by Region: 2021-2026
  4. 6.2.2 Global Paediatric Influenza Prevention Sales by Region (2027-2032)
  5. 6.3 Global Paediatric Influenza Prevention Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Paediatric Influenza Prevention Sales Value by Region (2021-2032)
  7. 6.4.1 Global Paediatric Influenza Prevention Sales Value by Region: 2021-2026
  8. 6.4.2 Global Paediatric Influenza Prevention Sales Value by Region (2027-2032)
  9. 6.5 Global Paediatric Influenza Prevention Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Paediatric Influenza Prevention Sales Value (2021-2032)
  12. 6.6.2 North America Paediatric Influenza Prevention Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Paediatric Influenza Prevention Sales Value (2021-2032)
  15. 6.7.2 Europe Paediatric Influenza Prevention Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Paediatric Influenza Prevention Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Paediatric Influenza Prevention Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Paediatric Influenza Prevention Sales Value (2021-2032)
  21. 6.9.2 South America Paediatric Influenza Prevention Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Paediatric Influenza Prevention Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Paediatric Influenza Prevention Sales Value Share by Country, 2025 VS 2032
7 Paediatric Influenza Prevention Country-level Sales and Value Analysis
  1. 7.1 Global Paediatric Influenza Prevention Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Paediatric Influenza Prevention Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Paediatric Influenza Prevention Sales by Country (2021-2032)
  4. 7.3.1 Global Paediatric Influenza Prevention Sales by Country (2021-2026)
  5. 7.3.2 Global Paediatric Influenza Prevention Sales by Country (2027-2032)
  6. 7.4 Global Paediatric Influenza Prevention Sales Value by Country (2021-2032)
  7. 7.4.1 Global Paediatric Influenza Prevention Sales Value by Country (2021-2026)
  8. 7.4.2 Global Paediatric Influenza Prevention Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Paediatric Influenza Prevention Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Paediatric Influenza Prevention Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Paediatric Influenza Prevention Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Paediatric Influenza Prevention Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Jiangsu GDK
  8. 8.2.1 Jiangsu GDK Company Information
  9. 8.2.2 Jiangsu GDK Business Overview
  10. 8.2.3 Jiangsu GDK Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Jiangsu GDK Paediatric Influenza Prevention Product Portfolio
  12. 8.2.5 Jiangsu GDK Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK Paediatric Influenza Prevention Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Viatris
  20. 8.4.1 Viatris Company Information
  21. 8.4.2 Viatris Business Overview
  22. 8.4.3 Viatris Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Viatris Paediatric Influenza Prevention Product Portfolio
  24. 8.4.5 Viatris Recent Developments
  25. 8.5 Sinovac
  26. 8.5.1 Sinovac Company Information
  27. 8.5.2 Sinovac Business Overview
  28. 8.5.3 Sinovac Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Paediatric Influenza Prevention Product Portfolio
  30. 8.5.5 Sinovac Recent Developments
  31. 8.6 KM Biologics
  32. 8.6.1 KM Biologics Company Information
  33. 8.6.2 KM Biologics Business Overview
  34. 8.6.3 KM Biologics Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 KM Biologics Paediatric Influenza Prevention Product Portfolio
  36. 8.6.5 KM Biologics Recent Developments
  37. 8.7 Hulan Bio
  38. 8.7.1 Hulan Bio Company Information
  39. 8.7.2 Hulan Bio Business Overview
  40. 8.7.3 Hulan Bio Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hulan Bio Paediatric Influenza Prevention Product Portfolio
  42. 8.7.5 Hulan Bio Recent Developments
  43. 8.8 CSL
  44. 8.8.1 CSL Company Information
  45. 8.8.2 CSL Business Overview
  46. 8.8.3 CSL Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CSL Paediatric Influenza Prevention Product Portfolio
  48. 8.8.5 CSL Recent Developments
  49. 8.9 CCBIO
  50. 8.9.1 CCBIO Company Information
  51. 8.9.2 CCBIO Business Overview
  52. 8.9.3 CCBIO Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CCBIO Paediatric Influenza Prevention Product Portfolio
  54. 8.9.5 CCBIO Recent Developments
  55. 8.10 BCHT
  56. 8.10.1 BCHT Company Information
  57. 8.10.2 BCHT Business Overview
  58. 8.10.3 BCHT Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 BCHT Paediatric Influenza Prevention Product Portfolio
  60. 8.10.5 BCHT Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Paediatric Influenza Prevention Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Paediatric Influenza Prevention Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Paediatric Influenza Prevention Value Chain Analysis
  2. 9.1.1 Paediatric Influenza Prevention Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Paediatric Influenza Prevention Sales Mode & Process
  6. 9.2 Paediatric Influenza Prevention Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Paediatric Influenza Prevention Distributors
  9. 9.2.3 Paediatric Influenza Prevention Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst